The integration of CeeNU into Septa’s lineup aims to stabilize the supply chain for a medication considered essential for patients battling severe cancer diagnoses. By absorbing this asset, the company strengthens its footprint in the Canadian critical care market while pledging to maintain uninterrupted access for medical professionals and their patients.

Devinder K., President and CEO of Septa Pharmaceuticals, stated that the company is currently coordinating with regulatory bodies and supply chain partners to manage a seamless transition of the drug’s distribution. Beyond this acquisition, Septa is actively pursuing new licensing and commercialization partnerships to broaden its reach in the global pharmaceutical sector, focusing on high-impact therapies.